Eterna Therapeutics Inc. (NASDAQ:ERNA) Short Interest Update

Eterna Therapeutics Inc. (NASDAQ:ERNA) saw a significant growth in short interest in the month of June. As of June 15th, there was short interest totalling 55,000 shares, a growth of 15.3% from the May 31st total of 47,700 shares. Based on an average daily volume of 7,100 shares, the short-interest ratio is currently 7.7 days. Approximately 2.0% of the company’s stock are short sold.

Institutional Trading of Eterna Therapeutics

Hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. grew its stake in Eterna Therapeutics by 30.6% in the third quarter. Vanguard Group Inc. now owns 24,898 shares of the company’s stock worth $54,000 after purchasing an additional 5,830 shares in the last quarter. Sippican Capital Advisors grew its stake in Eterna Therapeutics by 92.3% in the fourth quarter. Sippican Capital Advisors now owns 54,050 shares of the company’s stock worth $97,000 after purchasing an additional 25,950 shares in the last quarter. Lake Street Advisors Group LLC acquired a new position in Eterna Therapeutics in the fourth quarter worth about $933,000. Finally, Avidian Wealth Solutions LLC acquired a new position in Eterna Therapeutics in the first quarter worth about $36,000. Hedge funds and other institutional investors own 70.55% of the company’s stock.

Eterna Therapeutics Stock Performance

Shares of ERNA traded up $0.11 during mid-day trading on Wednesday, reaching $1.89. 1,289 shares of the stock traded hands, compared to its average volume of 8,478. The stock has a fifty day simple moving average of $1.94 and a 200 day simple moving average of $1.91. Eterna Therapeutics has a 12-month low of $0.84 and a 12-month high of $2.99. The company has a current ratio of 0.79, a quick ratio of 0.79 and a debt-to-equity ratio of 3.03.

Eterna Therapeutics (NASDAQ:ERNA) last posted its quarterly earnings data on Tuesday, May 14th. The company reported ($1.23) earnings per share (EPS) for the quarter. The firm had revenue of $0.05 million for the quarter.

About Eterna Therapeutics

Eterna Therapeutics Inc, a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited.